These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24642067)

  • 1. Noninvasive fetal RhD genotyping.
    Clausen FB; Damkjær MB; Dziegiel MH
    Transfus Apher Sci; 2014 Apr; 50(2):154-62. PubMed ID: 24642067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
    Clausen FB; Rieneck K; Krog GR; Bundgaard BS; Dziegiel MH
    Methods Mol Biol; 2019; 1885():347-359. PubMed ID: 30506209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
    Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
    Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.
    Manfroi S; Calisesi C; Fagiani P; Gabriele A; Lodi G; Nucci S; Pelliconi S; Righini L; Randi V
    Blood Transfus; 2018 Nov; 16(6):514-524. PubMed ID: 29757138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of maternal plasma for prenatal RhD blood group genotyping.
    Finning K; Martin P; Daniels G
    Methods Mol Biol; 2009; 496():143-57. PubMed ID: 18839110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women.
    Dündar Yenilmez E; Kökbaş U; Kartlaşmış K; Kayrın L; Tuli A
    PLoS One; 2018; 13(6):e0197855. PubMed ID: 29874251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RHD genotyping from maternal plasma: guidelines and technical challenges.
    Avent ND
    Methods Mol Biol; 2008; 444():185-201. PubMed ID: 18425481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic disease of the fetus and newborn in the molecular era.
    Fasano RM
    Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis.
    Clausen FB; Christiansen M; Steffensen R; Jørgensen S; Nielsen C; Jakobsen MA; Madsen RD; Jensen K; Krog GR; Rieneck K; Sprogøe U; Homburg KM; Grunnet N; Dziegiel MH
    Transfusion; 2012 Apr; 52(4):752-8. PubMed ID: 21995641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive antenatal RHD typing.
    Van der Schoot CE; Soussan AA; Koelewijn J; Bonsel G; Paget-Christiaens LG; de Haas M
    Transfus Clin Biol; 2006; 13(1-2):53-7. PubMed ID: 16564727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis.
    Zhu YJ; Zheng YR; Li L; Zhou H; Liao X; Guo JX; Yi P
    J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1839-44. PubMed ID: 24422551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study.
    Benachi A; Delahaye S; Leticee N; Jouannic JM; Ville Y; Costa JM
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):28-32. PubMed ID: 22386678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetal blood grouping using cell free DNA - an improved service for RhD negative pregnant women.
    Bills VL; Soothill PW
    Transfus Apher Sci; 2014 Apr; 50(2):148-53. PubMed ID: 24679596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population.
    Grande M; Ordoñez E; Cirigliano V; Cid J; Grau E; Pericot A; Teixido I; Marin JL; Borrell A
    Prenat Diagn; 2013 Feb; 33(2):173-8. PubMed ID: 23280558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping.
    Lo YM
    Transfus Clin Biol; 2006; 13(1-2):50-2. PubMed ID: 16563836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Noninvasive prenatal diagnosis from maternal plasma in serological conflicts in Poland: current practice and future prospects].
    Orzińska A; Guz K; Brojer E
    Ginekol Pol; 2009 Oct; 80(10):768-71. PubMed ID: 19943542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care.
    Clausen FB
    Prenat Diagn; 2014 May; 34(5):409-15. PubMed ID: 24431264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.